Drug class

Ophthalmic - Anti-Inflammatory, Immunomodulators

Ophthalmic anti-inflammatory immunomodulators are a therapeutic drug class used in formulary classifications and clinical practice guidelines to describe topical ocular agents that attenuate immune-driven ocular surface inflammation. Read more about Ophthalmic - Anti-Inflammatory, Immunomodulators

17 drugs in this class 15 manufacturers

Advertisement

Drugs in Ophthalmic - Anti-Inflammatory, Immunomodulators

Showing 1–9 of 17 drugs

XIIDRA (lifitegrast)

OPHTHALMIC - ANTI-INFLAMMATORY, IMMUNOMODULATORS · TEAR FILM INSUFFICIENCY
BAUSCH & LOMB P

CYCLOSPORINE

ANTIPSORIATICS · PREVENTION OF KIDNEY TRANSPLANT REJECTION ·+2
APOTEX CORP

CEQUA (cyclosporine)

OPHTHALMIC - ANTI-INFLAMMATORY, IMMUNOMODULATORS · KERATOCONJUNCTIVITIS SICCA
SUN PHARMA GLOB

VEVYE (cyclosporine)

OPHTHALMIC - ANTI-INFLAMMATORY, IMMUNOMODULATORS · TEAR FILM INSUFFICIENCY
HARROW EYE, LLC

XIIDRA (lifitegrast)

OPHTHALMIC - ANTI-INFLAMMATORY, IMMUNOMODULATORS · TEAR FILM INSUFFICIENCY
Novartis Pharmaceuticals

CYCLOSPORINE

OPHTHALMIC - ANTI-INFLAMMATORY, IMMUNOMODULATORS · KERATOCONJUNCTIVITIS SICCA
Mylan Pharmaceuticals

CYCLOSPORINE

OPHTHALMIC - ANTI-INFLAMMATORY, IMMUNOMODULATORS · KERATOCONJUNCTIVITIS SICCA
KVK-TECH, INC.

CYCLOSPORINE

OPHTHALMIC - ANTI-INFLAMMATORY, IMMUNOMODULATORS · KERATOCONJUNCTIVITIS SICCA
A-S MEDICATION
Filter & compare in the drug finder → Opens the drug finder with Ophthalmic - Anti-Inflammatory, Immunomodulators preselected. Add indication or manufacturer filters there.

About Ophthalmic - Anti-Inflammatory, Immunomodulators.

Ophthalmic anti-inflammatory immunomodulators are a therapeutic drug class used in formulary classifications and clinical practice guidelines to describe topical ocular agents that attenuate immune-driven ocular surface inflammation.

Represented primarily by calcineurin inhibitors, such as ophthalmic cyclosporine, and lymphocyte function-associated antigen-1 antagonists like lifitegrast, these agents work locally by inhibiting T-cell activation, migration, and the downstream release of proinflammatory cytokines.

By dampening local immune activity, they restore ocular surface homeostasis and improve functional tear production.

Their primary therapeutic applications include chronic dry eye disease (keratoconjunctivitis sicca) and severe allergic ocular surface disorders, such as vernal keratoconjunctivitis.